AI Article Synopsis
- The PRANDIAL study was conducted to assess the safety and effectiveness of lixisenatide for treating type 2 diabetes in Japanese individuals, as there was a lack of real-world evidence prior to this research.
- The study analyzed data from 3,046 participants, revealing that while adverse drug reactions (ADRs) occurred in 19.8% of cases, they were generally mild, with the most common being nausea.
- Significant improvements were observed in important health metrics like HbA1c and body weight, indicating that lixisenatide is effective for managing type 2 diabetes in this population.
Article Abstract
Introduction: Real-world evidence on lixisenatide in Japanese people with type 2 diabetes (T2D) is lacking. Therefore, the 3-year post-marketing PRANDIAL study was conducted to evaluate the safety (primary objective) and effectiveness (secondary objective) of lixisenatide in Japanese people with T2D during routine clinical practice.
Methods: This prospective, observational, multicenter, open-label study was conducted in Japanese individuals with T2D who initiated lixisenatide treatment between March 2014 and June 2017. Using electronic case report forms, investigators collected baseline demographic and clinical information and data on medications, safety and effectiveness up to 3 years after initiation of lixisenatide.
Results: Overall, 3046 participants were analyzed; their mean ± standard deviation (SD) age was 58.9 ± 13.1 years, and 53.7% were male. Mean ± SD duration of T2D was 12.8 ± 8.6 years, and baseline glycated hemoglobin (HbA1c) was 8.7% ± 1.7%. Most participants (93.9%) were receiving concomitant antidiabetic medications when they initiated lixisenatide. Median (range) lixisenatide treatment duration was 382 (1-1096) days. Adverse drug reactions (ADRs) were reported in 604 participants (19.8%) and serious ADRs in 22 (0.7%). The most common ADR was nausea (9.0%). Of ADRs of special interest, hypoglycemia occurred in 2.9% of participants, injection site reactions in 0.9%, and hypoglycemic unconsciousness in 0.03%. Baseline characteristics associated with an increased risk of ADRs (p < 0.05) were history of treatment for cardiovascular disease, hepatic dysfunction, and other complications. Effectiveness was analyzed in 2675 participants; HbA1c, fasting plasma glucose, postprandial glucose, and body weight all decreased significantly at last observation (all p < 0.0001 vs. baseline).
Conclusions: Lixisenatide was well tolerated, with no unexpected ADRs or new safety signals identified, and showed effective glycemic control and weight reduction up to 3 years, supporting the use of lixisenatide as a safe and effective treatment option for T2D in routine clinical practice in Japan.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122860 | PMC |
| http://dx.doi.org/10.1007/s12325-022-02121-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Quality of Life in Japanese People with Type 2 Diabetes Switching from Multiple Daily Insulin Injections to Once-Daily iGlarLixi: SIMPLIFY Japan.
Diabetes Ther
November 2024
Department of Diabetes, Endocrinology and Metabolism, and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.
Article Synopsis
- The SIMPLIFY Japan study examined the transition from multiple daily insulin injections to once-daily iGlarLixi in adults with moderately controlled type 2 diabetes (T2D).
- Over 24 weeks, participants showed significant improvements in health-related quality of life (HRQOL) scores, particularly in areas related to daily activities and treatment satisfaction, with minimal negative impact on glycemic control.
- Additionally, there was an increase in treatment adherence and a small weight reduction, but incidences of hypoglycemia and gastrointestinal side effects were noted among participants.
Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan.
Diabetes Ther
March 2024
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Article Synopsis
- The SPARTA Japan study confirmed that the combination of insulin glargine and lixisenatide (iGlarLixi) is effective and safe for treating type 2 diabetes in Japanese adults over six months.
- A post hoc analysis of the study looked at participant characteristics to see how these affected the achievement of glycemic targets based on age.
- Results showed that older individuals with lower baseline HbA1c levels were more likely to achieve their glycemic targets, with greater reductions in HbA1c and body weight seen in the achieved group compared to the not-achieved group.
Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.
Diabetes Obes Metab
January 2024
Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Article Synopsis
- The study aimed to compare the effectiveness of GIP/GLP-1 receptor agonists and GLP-1 receptor agonists in Japanese patients with type 2 diabetes (T2D).
- Researchers conducted a systematic review and network meta-analysis of randomized controlled trials (RCTs) to assess the impacts on glycated hemoglobin (HbA1c) levels and body weight.
- The findings indicated that tirzepatide 15 mg was the most effective in reducing HbA1c and body weight compared to subcutaneous and oral semaglutide, while both forms of semaglutide outperformed conventional GLP-1RAs like dulaglutide and liraglutide.
Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study.
Diabetes Ther
April 2023
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Introduction: iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL and the glucagon-like peptide 1 receptor agonist (GLP-1 RA) lixisenatide, is one option for treatment intensification in individuals with type 2 diabetes (T2D) who are unable to achieve targeted glycaemic control with their current glucose-lowering agent. Real-world data on the impact of prior treatment on the effectiveness and safety of iGlarLixi may be useful to guide individualised treatment decisions.
Methods: This analysis of the 6-month, retrospective, observational SPARTA Japan study compared glycated haemoglobin (HbA1c), body weight and safety for pre-specified subgroups defined by prior treatment: post oral antidiabetic agent (OAD), GLP-1 RA, basal insulin (BI) + OADs (BOT), GLP-1 RA + BI or multiple daily injections (MDI).
Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study.
Diabetes Ther
January 2023
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Introduction: Many individuals with type 2 diabetes (T2D) experience suboptimal glycemic control. Treatment intensification options include fixed-ratio combination products containing a basal insulin and a glucagon-like peptide-1 receptor agonist, such as iGlarLixi (insulin glargine 100 U/mL and lixisenatide). This study aimed to provide real-world evidence of the effect of iGlarLixi in Japanese clinical practice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!